D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions. In addition to testing efficacy, this trial will characterize DCS effects in terms of time course and persistence of response and will examine DCS effects on memory consolidation and cognitive flexibility as possible mediators of DCS enhancement of CBT for delusions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Cycloserine

Criteria

Inclusion Criteria:

• Age 18-68

• Diagnosis of schizophrenia, schizoaffective disorder, or delusional disorder

• Treated with any antipsychotic except clozapine for at least 8 weeks or antipsychotic naive for lifetime

• Willing to participate in CBT

• Sufficient proficiency in English to complete assessments

• Score of at least 3 on the SAPS at two assessments, four weeks apart

Exclusion Criteria:

• Current treatment with clozapine

• SSRI treatment

• Active alcohol or other substance abuse within six weeks

• Unstable medical illness

• Pregnant or nursing

• Anemia

• Renal insufficiency